Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Holdings (NASDAQ:COSM) announced the appointment of Dr. Anastasios Aslidis to its Board of Directors and audit committee. Dr. Aslidis, a finance expert with over 30 years in the maritime industry, currently serves as CFO for EuroDry and Euroseas. His extensive experience in corporate finance is expected to aid Cosmos in scaling its operations and expanding its international presence. CEO Greg Siokas expressed confidence in Dr. Aslidis's background, emphasizing its alignment with the company's growth strategy in the nutraceutical and pharmaceutical markets.

Cosmos Holdings (NASDAQ:COSM) reported revenue growth for 2021, achieving $56.2 million, up from $55.4 million in 2020. The company also recorded positive adjusted net income of $383,747 and adjusted EBITDA of $3.3 million. Cosmos continues to expand its product line and distribution network, with new premium nutraceuticals launched and growth into new markets including Asia and Europe. The company uplisted to NASDAQ in early 2022 and focuses on reducing debt, increasing working capital by 69% to $11 million.

Cosmos Holdings (NASDAQ:COSM) has announced the launch of Mediterranation, a premium line of nutritional supplements under its Sky Premium Life brand. This line utilizes organic herbs and plant extracts sourced from Greece and the Mediterranean, featuring ingredients known for their health benefits, including polyphenols with antioxidant properties. CEO Greg Siokas highlighted the anticipated demand for these high-quality supplements and the company's growth strategy to expand into new global markets. Manufacturing adheres to strict pharmaceutical standards, ensuring quality.

Cosmos Holdings (NASDAQ:COSM) announced the launch of its Sky Premium Life products on Amazon Singapore, achieving the rollout ahead of schedule, with plans for 15 SKUs initially and 85 SKUs by year-end. This move comes as the Singapore e-commerce market is expected to grow from $5.9 billion in 2021 to $10.7 billion by 2025, driven by increasing online shopping preferences.

CEO Greg Siokas emphasized the significance of this launch in expanding their global market strategy amidst rising demand for nutraceuticals.

Cosmos Holdings (NASDAQ:COSM) has launched Brainlit, a new brain health supplement under its luxury line, Sky Premium Life. This product aims to address rising brain-related conditions like Alzheimer's, affecting over 55 million globally. The brain health supplement market is projected to grow from $7.7 billion in 2020 to $19.7 billion by 2030, driven by an aging population and increased demand for effective treatments. The formula includes key ingredients like ginkgo biloba, glutamine, and L-tyrosine, contributing to enhanced cognitive function.

Cosmos Holdings (Nasdaq: COSM) announces the launch of Prostatium, a proprietary supplement aimed at enhancing prostate health and preventing symptoms of Benign Prostate Hyperplasia (BPH). With about 30 million men affected worldwide, Prostatium includes proven ingredients like Saw Palmetto and Lycopene, manufactured under stringent standards. The company aims to expand its product reach across Europe and North America while tapping into the growing demand for high-quality nutraceuticals. CEO Greg Siokas highlighted the importance of this unique formulation developed by their R&D team.

Cosmos Holdings (NASDAQ:COSM) announced its participation in the Virtual Growth Conference hosted by Maxim Group LLC on March 28-30, 2022, from 9:00 a.m. to 5:00 p.m. ET. Investors can access the Company's pre-recorded presentation over these three days. The event will cover various sectors, including Biotech, Clean Energy, and Healthcare, featuring presentations, fireside chats, and discussions with CEOs. Cosmos Holdings is an international pharmaceutical company specializing in nutraceuticals and distributing pharmaceuticals across Europe, Asia, and North America.

Cosmos Holdings (Nasdaq: COSM) announced significant milestones in a shareholder letter dated March 23, 2022. The company successfully uplisted to the Nasdaq and raised $6 million. Their 2021 initiatives included launching new nutraceutical products and establishing distribution deals on Amazon UK and Alibaba's Tmall. Cosmos aims for a 15-20% revenue growth in 2022, targeting $65 million while improving gross margins to 18%. The global nutraceutical market is projected to grow from $352.9 billion in 2021 to $658.1 billion by 2028, presenting a robust landscape for the company.